Malek, Fatemeh
[ 1 ] - The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran
Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the...
[ 2 ] - Lineage Switch in Childhood Leukemia: A Case Report and Review of Literature
Acute leukemia which is the most common cancer in children is a heterogeneous group of clonal malignancies. The conversion of the leukemic cell lineage during the course of the disease or later is termed lineage switch. It has been rarely reported in the literature. In leukemia lineage switch, conversions from lymphoblastic leukemia to myeloid leukemia or vice versa are reported. Herein, we rep...
[ 4 ] - ترومبوزیس به عنوان اولین تظاهر لوکمی در کودکان
ترومبوز وریدی و شریانی عارضه ای است که در کودکان به ندرت اتفاق می افتد و معمولاً در مواردی همچون استفاده از کاتتر ورید مرکزی ، بی تحرکی ، بیماری قلبی ، تروما ، بدخیمی ، جراحی ، عفونت ، کم آبی بدن ، شوک ، چاقی ، سندرم نفروتیک ، سندرم آنتی فسفولیپید و اختلالات انعقادی رخ می دهد. در این مقاله پسربچه 8 ساله ای گزارش شده است که از 2 هفته قبل از بستری ، دچار درد صبحگاهی در اندام تحتانی و استفراغ و از ...
[ 5 ] - A Prospective Triple-blind Randomized Trial on Safety and Efficacy of Abitant in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Background: Oral Aprepitant, a neurokinin-1 receptor antagonist, is suggested in combination with other antiemetic agents in preventing chemotherapy-induced nausea and vomiting(CINV) associated with emetogenic chemotherapeutic regimens in adolescents, but its efficacy and safety in pediatric patients more than six months are unknown. in this study, we used abitant drug (a generic name of Aprepi...
نویسندگان همکار